1. It has been shown in animals that substance P as well as acetylcholine releases endothelium-derived nitric oxide and evokes vasodilatation and that ATP-induced vasodilatation is partially mediated by nitric oxide. The aim of this study was to examine whether vasodilator effects of substance P and ATP are mediated by nitric oxide in humans.
INTRODUCTION
To examine endothelial function in humans, acetylcholine and substance P are frequently used on the assumption that the vasodilator effects of both agents are mediated by release of nitric oxide from the endothelium. Previous studies have shown that acetylcholine-induced vasodilatation is impaired but substance P-induced vasodilatation is not in many pathological states including atherosclerosis [l] , variant angina [2, 31 and congestive heart failure [4] . It has been implied that there may be selective impairment of muscarinic receptor-mediated release of nitric oxide from the endothelium in these pathological states.
It has been demonstrated in humans that acetylcholine-induced forearm vasodilatation is partially blocked by NG-monomethyl-L-arginine (L-NMMA), an inhibitor of nitric oxide synthesis , and that supplementation of L-arginine, a precursor of nitric oxide, augments acetylcholine-induced vasodilatation [6, 81. These results confirm that acetylcholineinduced vasodilatation is mediated partially by release of nitric oxide in human forearm vessels. Another endothelium-dependent vasodilator, substance P, also causes forearm vasodilatation [4, 9, 101. Substance P-induced vasodilatation may not be mediated by nitric oxide since animal experiments in vivo and in vitro suggest that substance P may cause endothelium-dependent vasodilatation mediated by endothelium-derived hyperpolarizing factor [ll] . It is also possible that substance P-induced vasodilatation is mediated by endothelium-derived prostacyclin [12] . In a recent study in humans, Panza et al. [lo] have shown that after infusion of L-NMMA the absolute values of forearm blood flow (FBF) induced by substance P were reduced. Thus, substance P-induced vasodilatation may also be mediated by nitric oxide in human forearm vessels. However, the decreases in resting blood flow by L-NMMA make the interpretation of the vasodilator effects of substance P difficult. Moreover, these findings need to be confirmed. Accordingly, in order to determine precisely in human forearms whether substance P-induced vasodilatation is mediated by nitric oxide, we examined substance P-induced changes in FBF before and after infusion of L-NMMA at 4 pmol/min (a usual dose) or 8 pmol/min (a high dose) for 5 min or L-arginine supplementation. We compared the effects of L-NMMA on substance P-induced vasodilatation with those on acetylcholine (an endothelium-dependent vasodilator)-and sodium nitroprusside (SNP, an endothelium-independent vasodilator)-induced vasodilatation. Furthermore, to examine whether substance P-induced vasodilatation is mediated by prostaglandins, we examined substance P-induced changes in FBF before and after pretreatment with oral indomethacin. We also determined whether ATP-induced vasodilatation is mediated by nitric oxide in human forearm vessels since it has also been considered that ATP-induced vasodilatation is partially mediated by nitric oxide ~3 1 .
METHODS

General procedure
Studies were performed in healthy subjects (aged 26 -t 3 years, ranging from 18 to 67 years; 33 males and two females) who volunteered for the study. Subjects were mainly young (18-29years of age), healthy male students at the university who volunteered for the study (n = 29). The other subjects (n = 6) in Experiment 4 were also volunteers (hospital employees) and were older (46-67 years of age) than the subjects in the other experiments. We were careful to exclude subjects with risk factors which impair endothelium-dependent vasodilatation. Each subject was screened by taking a careful history and physical examination in relation to risk factors of cardiovascular diseases such as hypertension, a family history of hypertension, smoking, diabetes mellitus, hypercholesterolaemia and also renal or hepatic diseases, and we confirmed they did not have such factors. If subjects were over 30years old, an ECG, a chest X-ray and blood chemistry were also examined. They were all within normal limits. The protocol was explained, and informed written consent was obtained from each subject. The study was approved by the Ethical Committee for Human Study in our institution. The study was carried out with subjects in a supine position and in an air-conditioned room at a room temperature of 25-26°C. Under local anaesthesia with 2% procaine, the left brachial artery was cannulated with a 20-gauge intravascular over-the-needle poly(tetrafluoroethylene) catheter for drug infusion. The catheter was connected by a three-way stopcock to a pressure transducer (Viggo-Spectramed, Oxnard, CA, USA.) for direct measurement of arterial pressure. The arterial line was kept open by infusing heparinized saline (0.1 ml/min) when no drug was being administered. counting pulse for pressure recordings.
Heart rate was obtained by a few minutes on arterial
Measurements of FBF
FBF was measured by a mercury-in-silastic straingauge plethysmograph with a venous occlusion technique [4, 7, 8, 141 . The strain gauge was placed approximately 5 cm below the antecubital crease. FBF (ml min-* 100 ml-' forearm) was calculated from the rate of increase in forearm volume while venous return from the forearm was prevented by inflating a cuff on the upper arm. The pressure in the venous occlusion or congesting cuff on the upper arm was 40mmHg. Circulation to the hand was arrested by inflating a cuff around the wrist. The wrist cuff was inflated before the determination of FBF and continuously throughout the measurements. Forearm vascular resistance was calculated by dividing the mean arterial pressure (diastolic pressure plus one-third of the pulse pressure in mmHg) by the FBF. These values are expressed as units throughout this report. An average of four flow measurements made at 15 s intervals, which were calculated by two authors independently, was used for later analysis.
Protocols
Forearm vascular responses to drugs were examined in the next five protocols which are schematically described in Fig. 1 . After the placement of cannulas and a strain-gauge plethysmograph, at least 15 rnin were allowed for subjects to become accustomed to the study condition before the experiments began. Five experiments were performed. Each experiment was carried out on different days and in different subjects.
In the first protocol, we examined forearm vasodilating responses to intra-arterial infusions of substance P and ATP at graded doses before and after intra-arterial infusion of L-NMMA at 4 pmol/min (n = 9). First, we examined FBF responses to intra-arterial infusions of substance P (0.4, 0.8, 1.6 and 3.2ng/min) [4] or ATP (0.5, 1.0, 2.0 and 3.0 pg/min) [14] for 2 min at each dose. FBF reached the steady state by 1 min after starting infusion of the drugs. The order of series of drug infusion was alternated. Infusion of the second drug was begun at least 15 min after the termination of the first drug when FBF had returned to the baseline value. After complete recovery from the second drug infusion, L-NMMA was infused intraarterially at 4 pmol/min for 5 min [5-71. Immediately after L-NMMA infusion, baseline parameters were obtained. Intra-arterial infusions of substance P and ATP were then performed in the same way as before L-NMMA infusion. Again, infusions of substance P and ATP were alternated. Fifteen Experiment 1. minutes after the final dose of the first drug, L-NMMA was infused again at 4pmol/min for 5 min. Baseline parameters were obtained and infusion of the second drug was performed. FBF and arterial pressure were continuously monitored and recorded during drug infusion. The last l m i n measurements of FBF during infusion of each dose of the drug were used for later analysis.
This protocol was performed in eight subjects. In this protocol, we determined whether infusion of L-NMMA at a higher dose (8 pmol/min) affected forearm vasodilating responses to intra-arterial infusions of substance P and acetylcholine because we did not see attenuated forearm vasodilating responses to substance P and ATP after infusion of L-NMMA (4pmol/min) in Experiment 1, although previous studies from our laboratory and others have shown that this dose of L-NMMA can partially block acetylcholine-induced forearm vasodilatation [5-71. We also determined the reproducibility of substance P-induced forearm vasodilatation in this group because there may be tachyphylaxis of substance P-induced vasodilatation [9] . First, we examined forearm vasodilating responses to intra-arterial infusions of substance P (0.8, 1.6 and 3.2ng/min) and acetylcholine (4, 8 and 12 pg/min). The order of series of drug infusion was alternated. Intra-arterial infusion of substance P was then repeated before infusion of L-NMMA (Fig. 1) . Abbreviations: SP, substance P; ACh, acetylcholine.
After complete recovery from the second infusion of substance P, L-NMMA was infused intra-arterially at 8 pmol/min for 5 min. Finally, infusions of substance P and acetylcholine were repeated. Measurements of variables were performed in the same way as in Experiment 1.
'
Experiment 3. This protocol was performed in seven subjects. We examined forearm vasodilating responses to SNP (0.8, 1.6 and 3.2pg/min), an endothelium-independent vasodilator, and substance P (0.8, 1.6 and 3.2 ng/min) before and after infusion of L-NMMA (8pmol/min for 5min). The order of series of drug infusion was alternated. Measurements of variables were performed in the same way as in Experiment 1.
Experiment 4. In this protocol in six subjects, we examined whether supplementation of L-arginine augmented substance P-induced vasodilatation. Substance P was infused at 0.25, 0.5, 1.0, 1.5 and 2.0ng/min for 2min at each dose. After complete recovery, L-arginine was infused at 10 mg/min. Ten minutes after starting infusion of L-arginine, forearm vasodilating responses to substance P were examined while L-arginine was simultaneously infused. We chose this dose of L-arginine because we have previously shown that it augments acetylcholine-induced forearm vasodilatation but does not affect resting FBF [8, 151 . Measurements of variables were performed in the same way as in Experiment 1. Although subjects in this experiment were older than those in the other experiments, we included them because we have previously shown that aging does not affect endothelium-dependent vasodilatation in the forearm [14] .
In this protocol in five subjects, we determined whether substance P-induced vasodilatation was mediated by prostaglandins. Substance P was infused at 0.8, 1.6 and 3.2ng/min for 2min at each dose. Indomethacin (75 mg) was then administered orally. Sixty minutes after indomethacin administration, infusion of substance P was repeated. Measurements of variables were performed in the same way as in Experiment 1.
Experiment 5.
Preparation of drugs
Substance P (Peptide Research Laboratories, Osaka, Japan) was diluted in physiological saline and was sterilized in the pharmaceutical section of our hospital. ATP, acetylcholine and SNP solution were prepared by dissolving 20mg of ATP (Kowa, Nagoya, Japan), 100 mg of acetylcholine chloride (Daiichi Pharmaceutical, Tokyo, Japan) and 10 mg of SNP (Wakou Junyaku Kogyo, Osaka, Japan) in physiological saline at a concentration of 5 pg/ml, 40 pg/ml and 4 pg/ml, respectively, immediately before use. Special care was taken not to1 expose SNP to light. For the infusion of L-arginine, commercially available L-arginine solution (0.1 g of L-arginine hydrochloride/ml; Morishita Pharma-ceutical, Osaka, Japan) was used. L-NMMA was obtained from Clinalfa A G (Zurich, Switzerland) and was dissolved in physiological saline immediately before use.
Statistical analysis
The effects of L-NMMA, L-arginine and indomethacin on the resting values were analysed by paired t-test. The forearm haemodynamic values in response to drugs were analysed by one-way or two-way analysis of variance (ANOVA) when appropriate. All values are expressed as means & SEM and P < 0.05 was considered to be statistically significant.
RESULTS
Effects of L-NMMA on resting haemodynamic values
In Experiment 1, infusion of L-NMMA at a low dose (4 pmol/min for 5 min, n = 9) decreased resting FBF (PxO.05, by paired t-test) and increased forearm vascular resistance (P<O.Ol) ( Table 1) . In Experiments 2 (n = 8) and 3 (n = 7), we infused a high dose (8pmol/min for 5 min) of L-NMMA which also decreased resting FBF (P<O.Ol) and increased resting forearm vascular resistance (P<O.Ol) (Tables 2 and 3) . The magnitudes of decreases in FBF and increases in forearm vascular resistance evoked by the high dose of L-NMMA were greater (P < 0.05 by unpaired t-test) than those evoked by the low dose of L-NMMA. These doses of L-NMMA did not affect arterial pressure (Tables 1,  2 and 3) and heart rate (data not shown). Figure 2 shows representative plethysmographic recordings of FBF in a subject in response to intraarterial infusion of substance P at graded doses before and after infusion of L-NMMA at 4 pmol/min. Substance P increased FBF dosedependently before and after infusion of L-NMMA in Experiments 1, 2 and 3 (P<O.Ol, by one-way ANOVA). L-NMMA decreased resting FBF but did not alter FBF responses to substance P. summarizes forearm haemodynamic values in response to substance P and ATP before and after infusion of L-NMMA at 4 pmol/min. Table 2 summarizes forearm haemodynamic values in response to substance P and acetylcholine, and Table 3 summarizes forearm haemodynamic values in response to substance P and SNP, before and after infusion of L-NMMA at 8pmol/min. Infusion of any drug did not alter arterial pressure (Tables 1, 2 and 3) and heart rate (data not shown). After infusion of L-NMMA, the absolute values of FBF in response to any drug were less and the absolute values of forearm vascular resistance were greater than those before infusion of L-NMMA (Tables 1, 2 
Effects of L-NMMA on drug-induced vasodilatation
Reproducibility of substance P-induced vasodilatation
In Experiment 2, the magnitudes of vasodilator responses to the first and second series of infusions of substance P were similar (Fig. 5) .
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Effects of L-arginine on substance P-induced vasodilatation
In Experiment 4, intra-arterial infusion of L-arginine did not alter resting arterial pressure, FBF, forearm vascular resistance (Table 4 ) and heart rate (data not shown). L-Arginine did not alter vasodilator responses to substance P.
Effects of indornethacin on substance P-induced vasodilatation
In Experiment 5, oral administration of indomethacin (75 mg) did not alter resting arterial pressure, 
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FBF. forearm vascular resistance (Table 5) and DISCUSSION heart rate (data not shown). Forea;m vasodilating after indomethacin administration.
The major purpose of the present study was to tion in human forearms is mediated bv nitric oxide responses to substance did not differ before and determine whether substance P-induced vasodilata- We performed this experiment because acetylcholine and substance P are frequently used to examine endothelial function in humans on the assumption that both drugs cause vasodilatation by releasing nitric oxide from the endothelium. It has been reported in many pathological states including atherosclerosis [l], variant angina [2, 31 and heart failure [4] that acetylcholine-induced vasodilatation is impaired but substance P-induced vasodilatation is preserved in the coronary vasculature or forearm vasculature. These findings are interpreted as selective impairment of muscarinic receptors to release nitric oxide although there may be enhanced smooth muscle sensitivity to the muscarinic effects of acetylcholine in the case of large coronary artery. In a recent study, Panza et al. [lo] reported that patients with essential hypertension have impaired endothelium-dependent vasodilator responses to both acetylcholine and substance P, indicating that the endothelial abnormality in this condition is not restricted to the muscarinic receptor. In their study, substance P-induced vasodilatation was reduced after infusion of L-NMMA (4 pmol/min for 5 min) in normal subjects. Thus, it was suggested that substance P-induced vasodilatation is also mediated by release of nitric oxide from the endothelium. We cannot fully explain the differences between the results of their study and ours. However, based on the following findings, we think that substance P-induced forearm vasodilatation may not be mediated by the release of nitric oxide from the endothelium. First of all, we used not only a low dose but also a high dose of L-NMMA to inhibit nitric oxide formation. Previous investigators used only the low dose of L-NMMA (4pmol/min for 5 min) [6] [7] [8] 101 . In this study, before L-NMMA infusion, acetylcholine and substance P similarly increased FBF from 4.3 _+ 1.1 to 15.6 _+ 3.0 ml min-' 100 ml-' and from 4.7k1.6 to 17.1 k4.5 ml min-' 100 ml-l, respectively ( Table 2 ). The high dose of L-NMMA (8 pmol/min for 5 min) significantly attenuated increases in FBF induced by acetylcholine (from 2.5k0.6 to 5.4k1.3 ml min-' 100 ml-I), whereas substance P still increased FBF from 2.6k0.7 to 10.7k1.7 ml min-' 100 ml-' after L-NMMA infusion (Table 2) . Secondly, the normalized FBF (the percentage changes) was used for analysis. The high dose of L-NMMA attenuated acetylcholine-induced increases in normalized FBF but did not affect substance P-induced increases [ Fig. 4(top) ]. Thirdly, we examined vasodilator responses to SNP (an endothelium-independent vasodilator) before and after infusion of L-NMMA because it was possible that changes in resting forearm vessel tone induced by L-NMMA would affect the degree of vasodilatation to substance P.
Decreases in resting FBF after infusion of L-NMMA were similar for SNP and substance P ( Table 3) , and relative vasodilatation (normalized FBF responses) to both agents was similar [ Fig. 4(bottom) ]. Finally, although it has been shown that supplementation with L-arginine augments acetylcholine-induced vasodilatation [7, 8, 101 , supplementation with L-arginine did not augment substance P-induced vasodilatation in this study. Taken together, we think that substance P-induced forearm vasodilatation is mediated mostly by other mechanisms such as endothelium-dependent hyperpolarizing factor [ 11, 16, 171 rather than nitric oxide. It is also possible, however, that there may be a small component of nitric oxide to substance P-induced vasodilatation.
If the vasodilatation evoked by substance P is not mediated by nitric oxide, the interpretation of the discordant effects between acetylcholine and substance P would be different. Although we could not determine the mechanisms underlying substance P-induced vasodilatation in humans, results in animals in vitro and in vivo suggest that substance P may release endothelium-derived hyperpolarizing factors [ l l , 16, 171 and relax vascular smooth muscle. Thus, from our results, it may be possible that preserved substance P-induced vasodilatation in some pathological states is caused by intact vasodilator mechanisms involving endothelium-derived hyperpolarizing factors, although we cannot measure the membrane potential in the human vascular endothelium in vivo.
Because the plethysmographic measurements allowed us to examine forearm vasodilator responses of resistance vessels but not those of conduit vessels, we were unable to determine whether vasodilatation in response to substance P in the conduit vessels was mediated by nitric oxide. Chester et al. [18, 191 demonstrated that substance P-induced vasodilatation of excised human epicardial coronary arteries was inhibited by L-NMMA. We do not know the mechanism underlying the different effects of L-NMMA on substance P-induced vasodilatation in forearm resistance vessels and epicardial conduit vessels. It is possible that the contribution of nitric oxide to substance P-induced vasodilatation may differ between vascular beds. In fact, it has been reported that substance P caused disparate effects on systemic and coronary haemodynamics in conscious dogs, i.e. vasodilatation in the systemic circulation and vasoconstriction in the coronary circulation [20] , and that the substance P-mediated relaxing effect was more potent in distal than in proximal arterial segments in human epicardial coronary arteries [21] . Therefore, these data suggest that the contribution of nitric oxide to substance P-induced vasodilatation may depend on the organ or the size of the arteries.
We also examined whether substance P-induced vasodilatation is mediated by vasodilatory prostaglandins in the human forearm by examining FBF responses to substance P before and after indomethacin. Substance P increased FBF but substance P-induced forearm vasodilatation was not affected by indomethacin. From this evidence, we concluded that vasodilatory prostaglandins may not contribute to substance P-induced vasodilatation. Because indomethacin at 75 mg did not alter resting forearm vascular resistance, it is possible that the dose of indomethacin may not have been enough to inhibit prostacyclin synthesis. However, the failure of indomethacin to inhibit substance P-induced vasodilatation was probably not due to the inadequate dose as it was shown previously that plasma concentrations of indomethacin reached levels of 0.9 to 4pg/ml at 1 h after oral administration of 50mg [22] , concentrations sufficient to inhibit production of prostaglandins [23] . In addition, this dose of indomethacin did not change resting FBF in humans L-NMMA did not affect ATP-induced vasodilatation in this study. Although we did not test whether a higher dose of L-NMMA inhibited ATP-induced vasodilatation and whether supplementation of L-arginine augmented ATP-induced vasodilatation, it is not likely from the same lines of discussion that ATP-induced vasodilatation in the human forearm is mediated by nitric oxide. Results of animal experiments also suggest that ATP relaxes vascular smooth muscle by directly acting on the adenosine receptors of vascular smooth muscle [25-271. ~4 1 .
CONCLUSION
In forearm vessels of the healthy subjects, intraarterial infusion of L-NMMA did not affect substance P-and ATP-induced vasodilatation. In addition, supplementation of L-arginine did not augment, and pretreatment of indomethacin did not attenuate, substance P-induced vasodilatation. Thus, our results suggest that substance P-induced vasodilatation may be mediated by neither nitric oxide nor prostaglandins in the human forearm and that ATP-induced vasodilatation may not be mediated by nitric oxide.
